Long QT syndrome type 2 is a life-threatening disorder of cardiac electrophysiology. It can lead to sudden cardiac death as a result of QT prolongation and can remain undetected until it presents c... Lay abstract Long QT syndrome is a condition which is characterized by an abnormally lengthened time period of electrical activity in the heart. This abnormality can result in the initiation of hea...
Background: Abdominal aortic aneurysm (AAA) has a prevalence of 4.8%. AAA rupture is associated with significant mortality, thus surgical intervention is generally required once the aneurysm diameter exceeds 5.5 cm. Endovascular aneurysm repair (EVAR) is the predominant repair modality for AAA. However, in patients with complex aortic anatomy, fenestrated or branched EVAR is a superior repair option vs standard EVAR. Fenestrated and branched endoprostheses can be off-the-shelf or custom-made, which offers a more individualised approach. Aim: To summarise and evaluate the clinical outcomes achieved by fenestrated EVAR (FEVAR) and branched EVAR (BEVAR), and to explore the role of custom-made endoprostheses in contemporary AAA management. Methods: A literature search using Ovid Medline and Google Scholar was conducted to identify literature pertaining to the use and outcomes of fenestrated, branched, fenestrated-branched and custom-made endoprostheses for AAA repair. Results: FEVAR is an effective repair modality for patients with AAA that offers similar early survival, improved early morbidity but higher rates of reintervention in comparison to open surgical repair (OSR). Compared with standard EVAR, FEVAR is associated with similar in-hospital mortality yet higher rates of morbidity, especially regarding renal outcomes. BEVAR outcomes are rarely reported exclusively in the context of AAA repair. When reported, BEVAR is an acceptable alternative to EVAR in the treatment of complex aortic aneurysms and has similar reported complication issues to FEVAR. Custom-made grafts are a good alternative treatment option for complex aneurysms where hostile aneurysm anatomy precludes the use of conventional EVAR and sufficient time is available for the manufacturing of such devices. Conclusion: FEVAR offers a very effective treatment for patients with complex aortic anatomy and has been well-characterised over the past decade. RCTs and longer-term studies are desirable for unbiased comparison of non-standard EVAR modalities.
Study Design: A retrospective analysis of oncologist-provided prognoses vs actual survival outcomes of patients referred with Metastatic spinal cord compression (MSCC) to a supra-regional multidisciplinary team (MDT). Objectives: Prognostic scoring systems, such as the revised Tokuhashi, are commonly used to help guide the treatment of MSCC. However, scoring systems do not accommodate for the improved outcomes of contemporary cancer therapy. Oncologist-provided prognoses play an important role in real world rapid decision making. There is a paucity of evidence assessing the accuracy of the oncologist-provided prognosis. We conducted a retrospective study to evaluate this. Methods: Data was captured between January 2015 and December 2018. Patients were split into 2 groups: Group 1 (prognosis estimated 6 months). Median overall survival (mOS) and hazard ratio for death (HR) was assessed. Receiver operating characteristic (ROC) analysis was performed to assess the accuracy of the oncologist’s prognosis. Results: 829 patients were included. mOS in Group 1 was 5.8 months (95% CI 4.2-7.4 m), and in Group 2 mOS was not reached. Log rank test gave a Chi 2 of 131 ( P < .001). Cox regression analysis revealed a HR of .30 ( P < .001). Area under the ROC curve was 78%. Conclusions: Oncologist-provided prognosis is accurate in this cohort of unselected, consecutive MSCC patients. It reduced reliance on scoring systems that can become outdated. Given the rapid progress in cancer treatment, the oncologist’s prognostic prediction is integral in efficient and effective MSCC management to help rapidly determine surgical candidacy.
Background: Olfactory dysfunction (OD) is an increasingly recognised but under investigated comorbidity of cystic fibrosis (CF). The prevalence, assessment methods, and management impact of OD in CF remain poorly characterised. Methods: PRISMA 2020-compliant systematic review; PROSPERO ID: CRD420251060317. Databases searched May 2025 (primary) and December 2025 (secondary). Inclusion: confirmed CF diagnosis, peer-reviewed publication, olfactory outcomes reported, English language. Joanna Briggs Institute critical appraisal was used. Narrative synthesis was the primary method; a pre-specified exploratory random-effects prevalence meta-analysis (DerSimonian–Laird; Freeman–Tukey sensitivity analysis) with adult/paediatric subgroup analysis was conducted. Results: 29 papers (21 unique study populations) were included. 15 distinct assessment instruments were identified. Exploratory meta-analysis: pooled OD prevalence 58.9% (95% CI 44.6–72.3%; I²≈90–95%). Adults: 69.7% (95% CI 59.0–79.0%); paediatric: 29.8% (95% CI 13.5–51.7%). Pooled Sniffin’ Sticks Test score was 25.1± 5.6 versus normative 35.0 ± 4.2 (Cohen's d=2.51; hyposmic range). Pooled SNOT-22 was 41.2 ± 18.2 (moderate-to-severe disease). Pooled Lund-Mackay Score was 13.3 ± 5.0 (55.4% of maximum), indicating moderate-to-severe sinonasal burden. Highly effective modulator therapy consistently improved radiological markers of sinonasal disease; HRQoL improvement was variable and did not reach statistical significance in most studies. Psychophysical olfactory scores did not significantly improve in any included study. Conclusions: OD is prevalent and clinically significant in people with CF, with prevalence increasing with age. Heterogeneity in assessment methods limits inter-study comparability. Standardised multidimensional psychophysical testing and integration of olfactory screening into routine CF care are recommended. Prospective longitudinal studies, particularly commencing in childhood, are needed.